Company
lupengbio
Focused on designing and developing new anti-tumor drugs with significant highlights
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- 麓鹏制药有限公司
Claim, correct or request removal
Record updated 28 September 2026
About
麓鹏制药 (Lupeng Pharmaceutical) focuses on developing a new generation of small-molecule targeted innovative drugs for malignant tumors and autoimmune diseases, targeting key targets such as BTK, Bcl-2 and Bcl-xL in hematologic malignancies, with comprehensive plans for international and domestic multicenter clinical development and commercialization.
Products
- Other
- LP-108（乐托克拉, Lacutoclax）
- Other
- LP-118
- Other
- LP-168（洛布替尼, Rocbrutinib）
Loading relationship preview